Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 1;4(5):739-742.
doi: 10.1001/jamaoncol.2018.0049.

Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Shaodong Hong  1   2   3 , Fangfang Gao  1   2   3 , Sha Fu  4 , Yan Wang  5 , Wenfeng Fang  1   2   3 , Yan Huang  1   2   3 , Li Zhang  1   2   3
Affiliations

Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Shaodong Hong et al. JAMA Oncol. .

Abstract

This cohort study examines the association of concomitant genetics alterations with response to treatment with epidermal growth factor receptor tyrosine kinase inhibitors among patients with EGFR-mutant advanced non–small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Zhang has received research support from AstraZeneca, Eli Lilly, and Roche. No other disclosures were reported.

Figures

Figure.
Figure.. Genetic Alteration Profile of Circulating Tumor DNA (ctDNA) From Tyrosine Kinase Inhibitor (TKI)–Naive Patients With EGFR-Mutant Non–Small Cell Lung Cancer (NSCLC) and Its Association With Survival
A, Genetic mutations identified by targeted next-generation sequencing in the plasma of 58 patients with NSCLC harboring EGFR mutation in tumor tissue. The sequencing covers 49 cancer-related genes and involves 2659 Catalogue of Somatic Mutations in Cancer (COSMIC) mutations. B, Kaplan-Meier curves of progression-free survival (PFS) in patients whose ctDNA had concomitant mutations compared with those without concomitant mutations. C, Kaplan-Meier curves of overall survival (OS) in patients whose ctDNA had concomitant mutations compared with those without concomitant mutations. ARMS indicates amplification refractory mutation system; CR, complete response; del, deletion; EGFR, epidermal growth factor receptor; HR, hazard ratio; NR, not reached; PD, progressive disease; PR, partial response; SD, stable disease; seq, sequencing; and VAF, variant allele frequency.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lee JK, Hahn S, Kim DW, et al. . Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non–small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311(14):1430-1437. - PubMed
    1. Maemondo M, Inoue A, Kobayashi K, et al. ; North-East Japan Study Group . Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388. - PubMed
    1. Xu S, Lou F, Wu Y, et al. . Circulating tumor DNA identified by targeted sequencing in advanced-stage non–small cell lung cancer patients. Cancer Lett. 2016;370(2):324-331. - PMC - PubMed
    1. Blakely CM, Watkins TBK, Wu W, et al. . Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49(12):1693-1704. - PMC - PubMed
    1. Lee CK, Wu YL, Ding PN, et al. . Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol. 2015;33(17):1958-1965. - PubMed

MeSH terms